Kawasaki Disease After Vaccination

• DOI: 10.1097/inf.0b013e3181a66471
• Publication Date: 2009-10-23T15:41:23Z
• Authors: Wei Hua; Hector S. Izurieta; Barbara Slade; Ermias D. Belay; Penina Haber; Rosemary Tiernan; Emily Jane Woo; John Iskander; M Miles Braun; Robert Ball
• Keywords: Rotavirus vaccine

Kawasaki disease (KD) is a multisystemic vasculitis primarily affecting children<5 years. A review of RotaTeq (rotavirus vaccine live) clinical trial data revealed higher, though not statistically significantly, KD rates among vaccines than placebo recipients. In June 2007, the label was revised accordingly.To describe and assess reported to Vaccine Adverse Event Reporting System (VAERS) for all US licensed vaccines.We reviewed reports received by VAERS from 1990 through mid-October 2007. Cases were characterized age, gender, onset interval, type. Proportional reporting ratio (PRR) used evaluate each compared with others. calculated using number doses distributed as denominator.Through October 14, 107 VAERS: 26 categorized classic cases, 19 atypical, 52 possible, 10 noncases. Of 97 91% There no clustering intervals after day 1 postvaccination. Before revision, PRR elevated only Pediarix (DTaP, hepB, IPV combined) but rate (0.59/100,000 person-years) much lower background incidence (9-19/100,000 years in United States. After stimulated (1.47/100,000 still rate.Our does suggest an risk or other vaccines. Continued postmarketing monitoring ongoing.